Link Cell Therapies has started dosing kidney cancer patients with a CAR-T therapy engineered to attack only when two tumor markers appear together, and just boosted its Series A by $30 million to $90 million. A new CEO with SystImmune and Bristol Myers Squibb ties joins as the company chases a solid-tumor problem CAR-T has yet to solve.

— via Hoodline, John Becker